Immuneering Corp — Director's Dealing 2025

Feb 7, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2025-02-05

Reporting Person: Zeskind Benjamin J. (Director, PRESIDENT AND CEO, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-05	Stock Option	$1.91	A	480000	Acquired	2035-02-05	Class A Common Stock (480000)	Direct

Footnotes

F1: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2025, and will be fully vested and exercisable on January 1, 2029.